FDA-approved. Extensive clinical literature from TTrials, TRAVERSE study, AUA/EAU guidelines. Standard of care for hypogonadism. Key monitoring: total T, free T, E2, hematocrit, PSA, lipids every 3–6 months.
Testosterone replacement to physiologic levels in hypogonadal men. Primary mechanism: AR agonism → gene transcription for muscle protein synthesis, erythropoiesis, bone density, libido, mood, cognitive function. Key considerations: aromatization to E2 (monitor), hematocrit elevation, HPG axis suppression, testicular atrophy without adjuncts (HCG/Gonadorelin).
FDA-approved hypogonadism; AR agonism; monitor E2/hematocrit/PSA; HPG suppression requires HCG/Gonadorelin adjunct; TTrials and TRAVERSE outcome data.
Research data is not a treatment plan. If you are considering TRT Protocol, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.
Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.Interactive tools for this compound:
Reconstitution calculator · Full deep dive · Peptide fundamentals